<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572688</url>
  </required_header>
  <id_info>
    <org_study_id>RG0276</org_study_id>
    <nct_id>NCT01572688</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma</brief_title>
  <acronym>MM</acronym>
  <official_title>A Multicenter, Single Arm, Open Label Study of Autologous Stem Cell Transplantation With High Dose Melphalan in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Lanjin Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Lanjin Pharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of melphalan for&#xD;
      injection for autologous stem cell transplant in multiple myeloma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year Progression Free Survival</measure>
    <time_frame>20 months</time_frame>
    <description>Plan to enroll all trial subjects within 8 months and follow up 1 year for each subject after enrollment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>powder for injection, 200mg/m2, uses after reconstituted within 24 hours</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with greater or equal to 18 years, with a upper age limit of 65 years are&#xD;
             eligible.&#xD;
&#xD;
          -  Multiple myeloma patients, symptoms conform to diagnosis of multiple myeloma of&#xD;
             IMWG2003/WHO2008 criteria.&#xD;
&#xD;
          -  Patients with responsive disease after induction therapy not more than 6 courses of&#xD;
             treatment&#xD;
&#xD;
          -  A complete response&#xD;
&#xD;
          -  A very good partial response&#xD;
&#xD;
          -  A partial response&#xD;
&#xD;
          -  At least 4 weeks long from last cytotoxic treatment(exclude Bortezomib, thalidomide,&#xD;
             dexamethasone);&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 Patient has an absolute&#xD;
             neutrophil count of ≥1.5×109/L and platelet count≥80×109/L;&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;50ml/min by Cockcroft-Gault formula or collect urine&#xD;
             within 24 hours.&#xD;
&#xD;
          -  Patient with a total bilirubin ≤1.5 times of normal upper limit, AST,ALT≤2.5times of&#xD;
             normal upper limit;&#xD;
&#xD;
          -  Cardio-pulmonary function is adequate to conduct autologous stem cell transplant.&#xD;
&#xD;
          -  Ratio of body weight and ideal body weight &lt;175%;&#xD;
&#xD;
          -  All patients should have a life expectancy of more than 12 weeks&#xD;
&#xD;
          -  Signed informed consent form voluntarily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CD34 positive hematopoietic stem cell collected &lt;2.0×106/kg&#xD;
&#xD;
          -  Patients have a psychiatric history&#xD;
&#xD;
          -  Female subject is pregnant or breast-feeding&#xD;
&#xD;
          -  Patients are hypersensitive to this trial product or other alkylating agents&#xD;
&#xD;
          -  Participate of other clinical trials within the past 4 weeks Active CNS lesions&#xD;
&#xD;
          -  Concomitant of active infection or positive of HIV antibody&#xD;
&#xD;
          -  Concomitant of other un-healed malignancy&#xD;
&#xD;
          -  Left ventricular ejection fraction≤50%&#xD;
&#xD;
          -  Patients with serious thrombosis&#xD;
&#xD;
          -  Any severe concomitant disease that will expose study subjects to unacceptable risks.&#xD;
&#xD;
          -  Patients not suitable to enroll by investigators considerations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lugui Qiu, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematologic Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu G Qiu</last_name>
      <phone>+86-022-23909172</phone>
    </contact>
    <contact_backup>
      <last_name>Jian J Yu, Master</last_name>
      <phone>+8615336402751</phone>
      <email>yujj@lanjin.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

